The companies plan to codevelop Adaptive's ClonoSeq assay to measure minimal residual disease in ALL.
The partners will characterize patient immune response to two new investigational immunotherapies from Argos Therapeutics.
The company is using its MIRA assay internally and in research collaborations to identify biomarkers that can serve as the basis for immunotherapies.
Executives from Thermo Fisher Scientific, Qiagen, Danaher, Counsyl, Human Longevity, and Adaptive Biotechnologies provided business updates to conference goers.
An NGS-based assay was better at diagnosing CTCL than PCR-based tests, and could distinguish between malignant and benign skin lesions and identify recurrence.
The financing comes from new and existing investors and will be used to fund research and development of the firm's T cell and B cell receptor sequencing projects.
The partners will compare Adaptive Bio's clonoSeq MRD test with flow cytometry for accuracy and reliability in monitoring MRD in multiple myeloma patients.
The results need to be validated but demonstrate the clinical utility of a more sensitive screen for detecting minimal residual disease.
Adaptive hopes to develop a gold standard for immune sequencing using the combined technologies.
Adaptive Biotechnologies CEO Chad Robins will remain as CEO, and Sequenta CEO Tom Willis and CSO Malek Faham will join the senior leadership team.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.